TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6130291

Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg twice daily for two years
Number of subjects: 1285

Group type: COMPARATOR
Intervention: No further treatment (Control)
Number of subjects: 1285

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 1285
Study: 30352443

Group type: EXPERIMENTAL
Intervention: Ultra-Mini PCNL (UMP)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Flexible Ureteroscopy (FURS)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Shock Wave Lithotripsy (SWL)
Number of subjects: 180
Study: 30395021

Group type: EXPERIMENTAL
Intervention: Acupressure (5-minute duration, three times per day for 6 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (no acupressure intervention)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study: 27333088

Group type: EXPERIMENTAL
Intervention: Maraviroc (MVC) 150 mg
Number of subjects: 262

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Participants with moderate neuropsychological impairment at baseline
Number of subjects: 262
Study: 24563240

Group type: EXPERIMENTAL
Intervention: e-learning (e-CAMS)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: in-person CAMS training
Number of subjects: 215

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 215
Study: 22332800

Group type: EXPERIMENTAL
Intervention: 15 mg/day MMI
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: 30 mg/day MMI
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: 300 mg/day PTU
Number of subjects: 449

Group type: COMPARATOR
Intervention: MMI to PTU switch
Number of subjects: 449
Study: 19787388

Group type: EXPERIMENTAL
Intervention: Limb remote ischemic preconditioning (RIPC) induced twice (24 h and 1 h preoperatively) via three 5‐min cycles of ischemia and reperfusion on the left upper arm using a blood pressure cuff.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Limb remote ischemic preconditioning (RIPC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 17520260

Group type: EXPERIMENTAL
Intervention: Mud-bath treatment (12 mud packs and thermal baths)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no mud-bath treatment)
Number of subjects: 80
Study: 17956712

Group type: EXPERIMENTAL
Intervention: zoledronic acid 4 mg
Number of subjects: 422

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 422
Study: 15238233

Group type: EXPERIMENTAL
Intervention: Flavonoid-rich diet
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal iso-caloric diet
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Supplemented diet (green tea and soy products)
Number of subjects: 90
Study: 11082825

Group type: EXPERIMENTAL
Intervention: Nicotine transdermal patch
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 108
Study: 9349604

Group type: EXPERIMENTAL
Intervention: Troglitazone 400 mg twice daily for 2 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1347231

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.08 mg kg‐1 or 0.10 mg kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Atracurium 0.4 mg kg‐1 or 0.5 mg kg‐1
Number of subjects: 40
Study: 4016938

Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Indoprofen
Number of subjects: 72
Study: 30531191

Group type: COMPARATOR
Intervention: AGV revision
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Visco-Trabeculotomy (VT)
Number of subjects: 41
Study: 29472491

Group type: COMPARATOR
Intervention: Monthly sulfadoxine‐pyrimethamine and 2 doses of azithromycin (AZI‐SP)
Number of subjects: 1320

Group type: COMPARATOR
Intervention: Control (2 doses of sulfadoxine‐pyrimethamine)
Number of subjects: 1320

Group type: COMPARATOR
Intervention: Monthly sulfadoxine‐pyrimethamine
Number of subjects: 1320
Study: 26899387

Group type: EXPERIMENTAL
Intervention: 0.5 μg calcitriol orally twice a day for 3 days prior to surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selective vitamin D treatment for patients with postoperative hypocalcaemia (control)
Number of subjects: 0
Study: 24257721

Group type: EXPERIMENTAL
Intervention: Doubly labeled water (DLW) method for energy requirement assessment over 28 days
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Doubly labeled water (DLW) method for energy requirement assessment
Number of subjects: 217
Study: 23138590

Group type: EXPERIMENTAL
Intervention: Optimized temporary bi-ventricular (BiV) pacing
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional dual-chamber right ventricular (RV) pacing
Number of subjects: 38
Study: 20187283

Group type: EXPERIMENTAL
Intervention: Lean subjects
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Obese subjects
Number of subjects: 14

Group type: COMPARATOR
Intervention: Comparison between lean and obese subjects
Number of subjects: 14
Study: 17360232

Group type: EXPERIMENTAL
Intervention: Ximelagatran
Number of subjects: 7329

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 7329
Study: 16244280

Group type: EXPERIMENTAL
Intervention: Digital Subtraction Angiography (DSA)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Multi-detector row CT angiography
Number of subjects: 145
Study: 12087450

Group type: EXPERIMENTAL
Intervention: de Gramont
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Lokich
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: raltitrexed
Number of subjects: 6
Study: 9528716

Group type: EXPERIMENTAL
Intervention: Trovafloxacin (100 mg tablet)
Number of subjects: 625

Group type: COMPARATOR
Intervention: Ofloxacin (200 mg capsules, 2 capsules)
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Trovafloxacin
Number of subjects: 625

Group type: COMPARATOR
Intervention: Ofloxacin
Number of subjects: 625
Study: 7543060

Group type: EXPERIMENTAL
Intervention: G‐CSF (10 g/kg/day subcutaneously and daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no G‐CSF)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study: 2702989

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (2 x 125 mg, 3 x 125 mg, or 2 x 250 mg daily)
Number of subjects: 101
Study: 773500

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 65

Group type: COMPARATOR
Intervention: Penicillamine
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 65
Study: 30966869

Group type: EXPERIMENTAL
Intervention: Inpatient enhanced multidisciplinary care (EMC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Multidisciplinary rehabilitation (MR)
Number of subjects: 80
Study: 29356210

Group type: EXPERIMENTAL
Intervention: Primary care interventions for MSK pain conditions
Number of subjects: 2483

Group type: EXPERIMENTAL
Intervention: Knee pain due to osteoarthritis (OA)
Number of subjects: 2483

Group type: EXPERIMENTAL
Intervention: Age, manual work, longer pain duration, widespread pain, anxiety/depression scores
Number of subjects: 2483
Study: 27332770

Group type: EXPERIMENTAL
Intervention: Single induction chemotherapy regimen C (four cycles of vincristine, carboplatin, and temozolomide) followed by marrow-ablative chemotherapy and autologous hematopoietic cell rescue.
Number of subjects: 32
Study: 25169040

Group type: EXPERIMENTAL
Intervention: Bolus infusion of 2,000 μg sodium selenite immediately prior to surgery, followed by an additional dosage of 2,000 μg at ICU admission, and a further daily supplementation of 1,000 μg up to 10 days or ICU discharge
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Placebo administration at the same time points
Number of subjects: 1400
Study: 22076019

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day for 4 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 34
Study: 21118874

Group type: EXPERIMENTAL
Intervention: Integrated care
Number of subjects: 134

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 134
Study: 17391565

Group type: EXPERIMENTAL
Intervention: Extra-virgin olive oil (EVOO) with 1125 mg polyphenols/kg and 350 mg tocopherols/kg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Refined olive oil (ROO) with no polyphenols or tocopherols
Number of subjects: 28
Study: 15887255

Group type: EXPERIMENTAL
Intervention: Pulsed ELF magnetic field exposure (15 min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham session (15 min)
Number of subjects: 20
Study: 12831586

Group type: EXPERIMENTAL
Intervention: Protocol I (clomiphene citrate and gonadotrophins)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Protocol II (gonadotrophins started during clomiphene citrate administration)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Patients with premature LH surge in Protocol I
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Patients without premature LH surge in Protocol I
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Patients with premature LH surge in Protocol II
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Patients without premature LH surge in Protocol II
Number of subjects: 46
Study: 10511135

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 45
Study: 8561057

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (15% carbohydrate)
Number of subjects: 43

Group type: COMPARATOR
Intervention: High-carbohydrate diet (45% carbohydrate)
Number of subjects: 43
Study: 1841833

Group type: EXPERIMENTAL
Intervention: High-dose bovine surfactant (100 mg/kg birth weight)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Low-dose bovine surfactant (50 mg/kg birth weight)
Number of subjects: 164
Study: 6288396

Group type: EXPERIMENTAL
Intervention: Enprofylline 2 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enprofylline 2 + 4 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Theophylline 9.2 +/- 0.9 mg/kg
Number of subjects: 0
Study: 30298417

Group type: EXPERIMENTAL
Intervention: High concentration oxygen group
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard concentration oxygen group
Number of subjects: 94
Study: 29265379

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/d for 5 days)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo (matched for 5 days)
Number of subjects: 77
Study: 26782677

Group type: EXPERIMENTAL
Intervention: Intensive training programme and implementation of a 16-week pressure ulcer prevention protocol
Number of subjects: 1088

Group type: COMPARATOR
Intervention: Usual pressure ulcer prevention care
Number of subjects: 1088
Study: 24844460

Group type: EXPERIMENTAL
Intervention: Simulation-based instruction (SIM)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Lecture-based instruction (LEC)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups (SIM and LEC)
Number of subjects: 32
Study: 22538278

Group type: EXPERIMENTAL
Intervention: Tretinoin cyclodextrin complex (RA/CyD)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tretinoin (RA)
Number of subjects: 12
Study: 21149720

Group type: EXPERIMENTAL
Intervention: Motion perception
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonperception
Number of subjects: 0
Study: 17547484

Group type: EXPERIMENTAL
Intervention: Participants instructed to engage in self-presentation during interactions with romantic partners
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants interacting with opposite sex strangers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants evaluated by another person
Number of subjects: 0
Study: 15786486

Group type: EXPERIMENTAL
Intervention: Olanzapine (average dosage 12.3 mg/day)
Number of subjects: 10
Study: 11882225

Group type: EXPERIMENTAL
Intervention: rocuronium 0.6 mg.kg‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: rocuronium 0.9 mg.kg‐1
Number of subjects: 120

Group type: COMPARATOR
Intervention: suxamethonium 1.5 mg.kg‐1
Number of subjects: 120
Study: 9018658

Group type: EXPERIMENTAL
Intervention: Root block
Number of subjects: 42

Group type: COMPARATOR
Intervention: Subpubic block
Number of subjects: 42
Study: 7910207

Group type: EXPERIMENTAL
Intervention: HIV-1 inactivated Immunogen
Number of subjects: 103
Study: 3069238

Group type: EXPERIMENTAL
Intervention: Active treatment (Pharmalgen, D. pteronyssinus)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (histamine)
Number of subjects: 38
Study: 30878157

Group type: EXPERIMENTAL
Intervention: 20% dextrose/0.2% lidocaine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (0.2% lidocaine)
Number of subjects: 42
Study: 28929359

Group type: EXPERIMENTAL
Intervention: Molecular subtyping (BluePrint and MammaPrint)
Number of subjects: 5806

Group type: COMPARATOR
Intervention: Surrogate pathological subtyping (PS)
Number of subjects: 5806
Study: 26769021

Group type: EXPERIMENTAL
Intervention: Skype-guided self-help intervention
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Unguided self-help intervention
Number of subjects: 192

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 192
Study: 24674384

Group type: EXPERIMENTAL
Intervention: Calcium carbonate combined with calcitonin
Number of subjects: 64

Group type: COMPARATOR
Intervention: Lanthanum carbonate
Number of subjects: 64
Study: 22719796

Group type: EXPERIMENTAL
Intervention: Pharmacy surveillance using a web‐based surveillance tool to monitor drug prescribing and kidney function trends.
Number of subjects: 396

Group type: COMPARATOR
Intervention: Standard pharmacy services and CDS alerting (Control group).
Number of subjects: 396
Study: 18417517

Group type: EXPERIMENTAL
Intervention: Quantitative Ultrasound (QUS) measurements at the calcaneus
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Bone mineral density (BMD) measurements at the lumbar spine
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: QUS measurements at the calcaneus
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: DXA measurements
Number of subjects: 432
Study: 17984410

Group type: EXPERIMENTAL
Intervention: Training group (n = 32)
Number of subjects: 86
Study: 16027572

Group type: EXPERIMENTAL
Intervention: Levalbuterol 1.25 mg via nebulization
Number of subjects: 70

Group type: COMPARATOR
Intervention: Racemic albuterol 2.5 mg via nebulization
Number of subjects: 70
Study: 12002290

Group type: EXPERIMENTAL
Intervention: CO2 insufflation laparoscopic cholecystectomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Gasless abdominal wall lift laparoscopic cholecystectomy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 9699834

Group type: EXPERIMENTAL
Intervention: Non-bridging external fixation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bridging external fixation
Number of subjects: 60
Study: 8042234

Group type: EXPERIMENTAL
Intervention: Double-drug therapy (DT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triple-drug therapy (TT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cadaver graft recipients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Living-related graft recipients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early graft function recovery
Number of subjects: 0
Study: 2969564

Group type: EXPERIMENTAL
Intervention: Active lung reexpansion through a fiberoptic bronchoscope using a large volume syringe
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional fiberoptic bronchoscopy suction
Number of subjects: 30
Study: 7754792

Group type: EXPERIMENTAL
Intervention: TNF plus MLT
Number of subjects: 14

Group type: COMPARATOR
Intervention: TNF
Number of subjects: 14
Study: 430774

Group type: EXPERIMENTAL
Intervention: Reinforcement by interpersonal similarity at the time of the emergency visit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive written appeals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up telephone reinforcement
Number of subjects: 0
Study: 30795780

Group type: EXPERIMENTAL
Intervention: NNRTI resistance surveillance
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: NNRTI resistance surveillance including additional polymorphisms
Number of subjects: 46
Study: 27862577

Group type: EXPERIMENTAL
Intervention: Undiluted Gadobenate dimeglumine (GD) 0.1 mmol/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diluted Gadobenate dimeglumine (GD) 0.1 mmol/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ferumoxytol (FE) 4 mg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ferumoxytol (FE) 2 mg/kg
Number of subjects: 12
Study: 25471273

Group type: EXPERIMENTAL
Intervention: Sodium citrate (CIT) ingestion (500 mg kg(‐1) body mass)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (PLC; wheat flour)
Number of subjects: 16
Study: 23408532

Group type: EXPERIMENTAL
Intervention: High-Protein Diet (HPD)
Number of subjects: 88

Group type: COMPARATOR
Intervention: High-Carbohydrate Diet (HCD)
Number of subjects: 88
Study: 21403177

Group type: COMPARATOR
Intervention: report (received feedback reports)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: session (group sessions)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: face-to-face (personal interviews)
Number of subjects: 265

Group type: COMPARATOR
Intervention: control
Number of subjects: 265
Study: 19562475

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for 16 sessions
Number of subjects: 19

Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 19
Study: 17136040

Group type: EXPERIMENTAL
Intervention: alpha (s1)‐casein hydrolysate (150 mg/day for 30 days)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 16133549

Group type: EXPERIMENTAL
Intervention: rosuvastatin 40 mg/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 11133704

Group type: EXPERIMENTAL
Intervention: ICCE with an ACIOL
Number of subjects: 2000

Group type: COMPARATOR
Intervention: ICCE with aphakic spectacles (+11 dioptres)
Number of subjects: 2000
Study: 9270561

Group type: EXPERIMENTAL
Intervention: cM-T412 antibody infusion
Number of subjects: 71
Study: 8176056

Group type: EXPERIMENTAL
Intervention: Change in delay between leading and lagging bursts (experiment 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Change in frequency (experiment 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Change in intensity (experiment 3)
Number of subjects: 0
Study: 2885117

Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg daily combined with beta-adrenergic-blocking drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beta-adrenergic-blocking drugs alone (single therapy)
Number of subjects: 0
Study: 30803433

Group type: EXPERIMENTAL
Intervention: GAP portal access
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Routine consultation
Number of subjects: 1500
Study: 28486637

Group type: EXPERIMENTAL
Intervention: Neighborhood regeneration activities in 35 intervention areas (n = 4,197 subjects)
Number of subjects: 10892

Group type: EXPERIMENTAL
Intervention: Length of residence in regeneration neighborhoods
Number of subjects: 10892

Group type: COMPARATOR
Intervention: Control areas (n = 6,695 subjects)
Number of subjects: 10892
Study: 25342644

Group type: EXPERIMENTAL
Intervention: Parent-child intervention
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Child-only intervention
Number of subjects: 194

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 194
Study: 23426676

Group type: EXPERIMENTAL
Intervention: Beta-band activity (18-30 Hz) in parietal regions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High gamma band (>60 Hz) activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low gamma (<60 Hz) and alpha (∼10 Hz) bands
Number of subjects: 0
Study: 21962943

Group type: EXPERIMENTAL
Intervention: Combination of oral misoprostol (OM) and mechanical dilation with a double‐balloon catheter
Number of subjects: 122

Group type: COMPARATOR
Intervention: Oral misoprostol (OM) only
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Combination of oral misoprostol (OM) and mechanical dilation with a double‐balloon catheter (excluding cases with premature rupture of membranes)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Oral misoprostol (OM) only (excluding cases with premature rupture of membranes)
Number of subjects: 122
Study: 19223890

Group type: EXPERIMENTAL
Intervention: Terlipressin (group A)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Octreotide (group B)
Number of subjects: 324
Study: 17209328

Group type: EXPERIMENTAL
Intervention: CD4 cell count
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CD8 cell count
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CD19 cell count
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CD56 cell count
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Lymphocyte subset counts
Number of subjects: 25
Study: 12626756

Group type: EXPERIMENTAL
Intervention: Attended image with changes in any of the three central bars
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Attended image with changes only in the middle bar
Number of subjects: 11
Study: 10614032

Group type: EXPERIMENTAL
Intervention: 2.0 mg intravenous naloxone administered 2 minutes prior to ECT treatments
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (no naloxone)
Number of subjects: 9
Study: 8967882

Group type: EXPERIMENTAL
Intervention: LDL apheresis (1 day before and 5 days after PTCA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (PTCA without LDL apheresis)
Number of subjects: 36
Study: 1836766

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study: 6764321

Group type: EXPERIMENTAL
Intervention: Ganda 3.0/0.5
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ganda 1.0/0.2
Number of subjects: 48
Study: 30204301

Group type: EXPERIMENTAL
Intervention: Metabolic glycan labeling (Sia5Ac and GalNAc/GlcNAc)
Number of subjects: 0
Study: 26568032

Group type: EXPERIMENTAL
Intervention: Tosedostat (120 mg on days 1-21 or 180 mg continuously) with cytarabine (1 g/m2/d) or decitabine (20 mg/m2/d) every 35 days
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Tosedostat with cytarabine or decitabine
Number of subjects: 34
Study: 24286967

Group type: EXPERIMENTAL
Intervention: Baseline drinking to cope with negative affect
Number of subjects: 254